Compare EPM & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | MGNX |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.2M | 115.8M |
| IPO Year | 1996 | 2013 |
| Metric | EPM | MGNX |
|---|---|---|
| Price | $4.49 | $3.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $4.93 | $3.40 |
| AVG Volume (30 Days) | 412.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | ★ 10.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $43,229,621.00 | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $92.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.19 | $0.99 |
| 52 Week High | $5.70 | $3.50 |
| Indicator | EPM | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 73.39 |
| Support Level | $4.38 | $1.45 |
| Resistance Level | $4.63 | $3.50 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 37.17 | 75.44 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.